Nonpeptide αvβ3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative
摘要:
Subtle modifications were incorporated into the structure of clinical candidate 1. These changes were designed to maintain potency and selectivity while inducing changes in physical properties leading to improved pharmacokinetics in three species. This approach led to the identification of 4 as a potent, selective alpha(v)beta(3) receptor antagonist that was selected for clinical development based on an improved PK profile and efficacy demonstrated in an in vivo model of bone turnover. (C) 2004 Elsevier Ltd. All rights reserved.
Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB Agonists
作者:Wolfgang Froestl、Stuart J. Mickel、Roger G. Hall、Georg von Sprecher、Dietrich Strub、Peter A. Baumann、Felix Brugger、Conrad Gentsch、Joachim Jaekel
DOI:10.1021/jm00017a015
日期:1995.8
replacing the carboxylic acid group of GABA or baclofen derivatives with either the phosphinic acid or the methylphosphinic acid residue. Surprisingly, ethyl- and higher alkylphosphinic acid derivatives of GABA yielded novel GABAB antagonists, which are described in part 2 of this series. Structure-activity relationships of the novel GABAB agonists are discussed with respect to their affinities to GABAB
Nonpeptide αvβ3 antagonists. Part 10: In vitro and in vivo evaluation of a potent 7-methyl substituted tetrahydro-[1,8]naphthyridine derivative
作者:Michael J Breslin、Mark E Duggan、Wasyl Halczenko、George D Hartman、Le T Duong、Carmen Fernandez-Metzler、Michael A Gentile、Donald B Kimmel、Chih-Tai Leu、Kara Merkle、Thomayant Prueksaritanont、Gideon A Rodan、Sevgi B Rodan、John H Hutchinson
DOI:10.1016/j.bmcl.2004.06.040
日期:2004.9
Subtle modifications were incorporated into the structure of clinical candidate 1. These changes were designed to maintain potency and selectivity while inducing changes in physical properties leading to improved pharmacokinetics in three species. This approach led to the identification of 4 as a potent, selective alpha(v)beta(3) receptor antagonist that was selected for clinical development based on an improved PK profile and efficacy demonstrated in an in vivo model of bone turnover. (C) 2004 Elsevier Ltd. All rights reserved.